Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bronchopulmonary Dysplasia
U.S. FDA grants Surfaxin fast track designation for prevention and treatment of BPD
February 27th, 2006
Discovery Laboratories, Inc., (DSCO) announced that the United States Food & Drug Administration (FDA) has granted fast track designation to Discovery's lead product, Surfaxin, for the prevention and treatment of Bronchopulmonary Dysplasia (BPD, also known as chronic lung disease) in premature infants. BPD is a costly syndrome affecting premature infants. It is associated with surfactant deficiency and the prolonged use of mechanical ventilation and oxygen supplementation. Some premature babies are born with a lack of natural surfactant in their lungs. Without surfactant, the air sacs in the lungs collapse and are unable to absorb sufficient oxygen resulting in...
Source: Pharma Business Week (2006-02-27)
|
